We also analyzed the potential implications of EGFR gene mutation status, as identified by the serum proteomic classifier, for predicting clinical outcomes in patients with NSCLC who received EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.